Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 6/20 | 0.50 |
| ▸ | GSK3A | P49840 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19666573 | 1.00 | PIN1 (0.50) | PIN1GSK3AGSK3BCDK2KMT2A | |
| SCHEMBL19666697 | 0.90 | PIN1 (0.50) | PIN1GSK3AGSK3BCDK2KMT2A | |
| SCHEMBL1804937 | 0.90 | PIN1 (0.56) | PIN1GSK3AGSK3BCDK2KMT2A | |
| SCHEMBL17649495 | 0.88 | PIN1 (0.50) | PIN1GSK3AGSK3BCDK2KMT2A | |
| SCHEMBL17649493 | 0.88 | PIN1 (0.50) | PIN1GSK3AGSK3BCDK2KMT2A | |
| SCHEMBL20837955 | 0.88 | PIN1 (0.50) | PIN1GSK3AGSK3BCDK2KMT2A | |
| SCHEMBL14589028 | 0.86 | GSK3A (0.57) | PIN1GSK3AGSK3BCDK2KMT2A | |
| SCHEMBL1265079 | 0.86 | GSK3A (0.57) | PIN1GSK3AGSK3BCDK2KMT2A | |
| SCHEMBL1265078 | 0.86 | GSK3A (0.57) | PIN1GSK3AGSK3BCDK2KMT2A | |
| SCHEMBL18492821 | 0.85 | PIN1 (0.44) | PIN1GSK3AGSK3BCDK2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010555-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | CELGENE CORPORATION (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170348315-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORPORATION | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010555-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | TPMT, TYMP, ATIC | PIN1 1699/4885GSK3A 2381/4885GSK3B 2302/4885 |
| US-20170348315-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | TPMT, TYMP, ATIC | PIN1 1699/4885GSK3A 2381/4885GSK3B 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.